These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 7948056

  • 21. Sleep laboratory study of lormetazepam in older insomniacs.
    Vogel GW.
    Psychopharmacology Suppl; 1984; 1():69-78. PubMed ID: 6147842
    [Abstract] [Full Text] [Related]

  • 22. Anxiety or depression during withdrawal of hypnotic treatments.
    Lader M.
    J Psychosom Res; 1994; 38 Suppl 1():113-23; discussion 118-23. PubMed ID: 7799243
    [Abstract] [Full Text] [Related]

  • 23. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial.
    Fava M, Asnis GM, Shrivastava RK, Lydiard B, Bastani B, Sheehan DV, Roth T.
    J Clin Psychiatry; 2011 Jul; 72(7):914-28. PubMed ID: 21208597
    [Abstract] [Full Text] [Related]

  • 24. CAP variables and arousals as sleep electroencephalogram markers for primary insomnia.
    Terzano MG, Parrino L, Spaggiari MC, Palomba V, Rossi M, Smerieri A.
    Clin Neurophysiol; 2003 Sep; 114(9):1715-23. PubMed ID: 12948801
    [Abstract] [Full Text] [Related]

  • 25. Why low-dose benzodiazepine-dependent insomniacs can't escape their sleeping pills.
    Schneider-Helmert D.
    Acta Psychiatr Scand; 1988 Dec; 78(6):706-11. PubMed ID: 2906215
    [Abstract] [Full Text] [Related]

  • 26. Pilot controlled double-blind study of the hypnotic effects of zolpidem in patients with chronic 'learned' insomnia: psychometric and polysomnographic evaluation.
    Herrmann WM, Kubicki ST, Boden S, Eich FX, Attali P, Coquelin JP.
    J Int Med Res; 1993 Dec; 21(6):306-22. PubMed ID: 8143886
    [Abstract] [Full Text] [Related]

  • 27. Objective and subjective sleep quality: Melatonin versus placebo add-on treatment in patients with schizophrenia or bipolar disorder withdrawing from long-term benzodiazepine use.
    Baandrup L, Glenthøj BY, Jennum PJ.
    Psychiatry Res; 2016 Jun 30; 240():163-169. PubMed ID: 27107670
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Midazolam: dose-response studies of effectiveness and rebound insomnia.
    Kales A, Soldatos CR, Bixler EO, Goff PJ, Vela-Bueno A.
    Pharmacology; 1983 Jun 30; 26(3):138-49. PubMed ID: 6132414
    [Abstract] [Full Text] [Related]

  • 30. Correlates of benzodiazepine use in individuals with insomnia.
    Morin CM, Bélanger L, Bernier F.
    Sleep Med; 2004 Sep 30; 5(5):457-62. PubMed ID: 15341890
    [Abstract] [Full Text] [Related]

  • 31. Zolpidem and rebound insomnia--a double-blind, controlled polysomnographic study in chronic insomniac patients.
    Monti JM, Attali P, Monti D, Zipfel A, de la Giclais B, Morselli PL.
    Pharmacopsychiatry; 1994 Jul 30; 27(4):166-75. PubMed ID: 7972349
    [Abstract] [Full Text] [Related]

  • 32. Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study.
    Hajak G, Rodenbeck A, Voderholzer U, Riemann D, Cohrs S, Hohagen F, Berger M, Rüther E.
    J Clin Psychiatry; 2001 Jun 30; 62(6):453-63. PubMed ID: 11465523
    [Abstract] [Full Text] [Related]

  • 33. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study.
    Bes F, Hofman W, Schuur J, Van Boxtel C.
    Neuropsychobiology; 1992 Jun 30; 26(4):193-7. PubMed ID: 1299794
    [Abstract] [Full Text] [Related]

  • 34. Rebound insomnia: its determinants and significance.
    Roehrs T, Vogel G, Roth T.
    Am J Med; 1990 Mar 02; 88(3A):39S-42S. PubMed ID: 1968719
    [Abstract] [Full Text] [Related]

  • 35. A 2-week efficacy and safety study of gaboxadol and zolpidem using electronic diaries in primary insomnia outpatients.
    Hajak G, Hedner J, Eglin M, Loft H, Stórustovu SI, Lütolf S, Lundahl J, Gaboxadol Study 99775 Group.
    Sleep Med; 2009 Aug 02; 10(7):705-12. PubMed ID: 19346160
    [Abstract] [Full Text] [Related]

  • 36. Effects of zolpidem on cyclic alternating pattern, an objective marker of sleep instability, in Japanese patients with psychophysiological insomnia: a randomized crossover comparative study with placebo.
    Ozone M, Yagi T, Itoh H, Tamura Y, Inoue Y, Uchimura N, Sasaki M, Shimizu T, Terzano MG, Parrino L.
    Pharmacopsychiatry; 2008 May 02; 41(3):106-14. PubMed ID: 18484552
    [Abstract] [Full Text] [Related]

  • 37. Placebo-controlled sleep laboratory studies on the acute effects of zolpidem on objective and subjective sleep and awakening quality in nonorganic insomnia related to neurotic and stress-related disorder.
    Saletu-Zyhlarz G, Anderer P, Brandstätter N, Dantendorfer K, Gruber G, Mandl M, Ritter K, Zoghlami A, Saletu B.
    Neuropsychobiology; 2000 May 02; 41(3):139-48. PubMed ID: 10754428
    [Abstract] [Full Text] [Related]

  • 38. Can valerian improve the sleep of insomniacs after benzodiazepine withdrawal?
    Poyares DR, Guilleminault C, Ohayon MM, Tufik S.
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Apr 02; 26(3):539-45. PubMed ID: 11999905
    [Abstract] [Full Text] [Related]

  • 39. Lorazepam-efficacy, side effects, and rebound phenomena.
    Scharf MB, Kales A, Bixler EO, Jacoby JA, Schweitzer PK.
    Clin Pharmacol Ther; 1982 Feb 02; 31(2):175-9. PubMed ID: 6120058
    [Abstract] [Full Text] [Related]

  • 40. Quazepam and flurazepam: long-term use and extended withdrawal.
    Kales A, Bixler EO, Soldatos CR, Vela-Bueno A, Jacoby J, Kales JD.
    Clin Pharmacol Ther; 1982 Dec 02; 32(6):781-8. PubMed ID: 7140142
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.